IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2004;45:4190-4196.)
© 2004 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.04-0676
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Paskowitz, D. M.
Right arrow Articles by Duncan, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paskowitz, D. M.
Right arrow Articles by Duncan, J. L.

BDNF Reduces the Retinal Toxicity of Verteporfin Photodynamic Therapy

Daniel M. Paskowitz,1,2 George Nune,1 Douglas Yasumura,1,3 Haidong Yang,1 Robert B. Bhisitkul,1 Shivani Sharma,1 Michael T. Matthes,1 Marco A. Zarbin,4 Matthew M. LaVail,1,3 and Jacque L. Duncan1

1From the Department of Ophthalmology, 2Medical Scientist Training Program and Neuroscience Graduate Program, and the 3Department of Anatomy, University of California, San Francisco, California; and the 4Institute of Ophthalmology and Visual Science, University of Medicine and Dentistry of New Jersey, Newark, New Jersey.

PURPOSE. Verteporfin photodynamic therapy (PDT) is the most effective treatment for age-related macular degeneration, using laser activation of a photosensitizing dye to achieve closure of choroidal neovascularization. Although PDT preferentially affects pathologic vessels, it can also cause collateral damage to the overlying retina. In the current study, it was found that the neuroprotective agent brain-derived neurotrophic factor (BDNF) reduces this retinal damage.

METHODS. Normal adult rats received intravitreal BDNF in one eye and PBS or no injection in the other eye 2 days before PDT.

RESULTS. Control eyes exhibited choroidal hypofluorescence, moderate to severe photoreceptor loss, and depression of local retinal function measured using multifocal ERG in the laser-treated area. BDNF-injected eyes had more surviving photoreceptors and improved multifocal ERG responses 1 week after PDT. BDNF did not diminish the effect of PDT on the choroidal circulation as assessed by fluorescein angiography, and there was no evidence of retinal toxicity due to BDNF treatment.

CONCLUSIONS. These results suggest that adjunctive neuroprotective therapy may reduce collateral damage to photoreceptors and improve visual outcome after PDT.




This article has been cited by other articles:


Home page
 IOVSHome page
H. She, T. Nakazawa, A. Matsubara, E. Connolly, T. Hisatomi, K. Noda, I. Kim, E. S. Gragoudas, and J. W. Miller
Photoreceptor Protection after Photodynamic Therapy Using Dexamethasone in a Rat Model of Choroidal Neovascularization
Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 5008 - 5014.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
R. B. Bhisitkul, B. J. Winn, O.-T. Lee, J. Wong, D. d. S. Pereira, T. C. Porco, X. He, P. Hahn, and J. L. Dunaief
Neuroprotective Effect of Intravitreal Triamcinolone Acetonide against Photoreceptor Apoptosis in a Rabbit Model of Subretinal Hemorrhage
Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 4071 - 4077.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
T. J. McGill, G. T. Prusky, R. M. Douglas, D. Yasumura, M. T. Matthes, G. Nune, K. Donohue-Rolfe, H. Yang, D. Niculescu, W. W. Hauswirth, et al.
Intraocular CNTF Reduces Vision in Normal Rats in a Dose-Dependent Manner
Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5756 - 5766.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
H. She, T. Nakazawa, A. Matsubara, T. Hisatomi, T. A. Young, N. Michaud, E. Connolly, A. Hafezi-Moghadam, E. S. Gragoudas, and J. W. Miller
Reduced Photoreceptor Damage after Photodynamic Therapy through Blockade of Nitric Oxide Synthase in a Model of Choroidal Neovascularization
Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2268 - 2277.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
D. M. Paskowitz, K. M. Donohue-Rolfe, H. Yang, D. Yasumura, M. T. Matthes, K. Hosseini, C. M. Graybeal, G. Nune, M. A. Zarbin, M. M. LaVail, et al.
Neurotrophic Factors Minimize the Retinal Toxicity of Verteporfin Photodynamic Therapy
Invest. Ophthalmol. Vis. Sci., January 1, 2007; 48(1): 430 - 437.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Bioactive and Compatible PolymersHome page
R. Sweitzer, C. Scholz, S. Montezuma, and J. F. Rizzo III
Evaluation of Subretinal Implants Coated with Amorphous Aluminum Oxide and Diamond-like Carbon
Journal of Bioactive and Compatible Polymers, January 1, 2006; 21(1): 5 - 22.
[Abstract] [PDF]

Home page
 IOVSHome page
R. Tzekov, T. Lin, K.-M. Zhang, B. Jackson, A. Oyejide, W. Orilla, A. D. Kulkarni, B. D. Kuppermann, L. Wheeler, and J. Burke
Ocular Changes after Photodynamic Therapy
Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 377 - 385.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Association for Research in Vision and Ophthalmology